Evidence map›Paper›PMID 35418206›Full record

ArticleRadiation oncology (London, England)2022

Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort.

Natalie Si-Yi Lee, Jesmin Shafiq, Matthew Field, Caroline Fiddler, Suganthy Varadarajan, Senthilkumar Gandhidasan, Eric Hau, Shalini Kavita Vinod

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Natalie Si-Yi LeeSouth Western Sydney Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia.
Jesmin ShafiqSouth Western Sydney Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia.
Matthew FieldSouth Western Sydney Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia.
Caroline FiddlerIllawarra Cancer Care Centre, Wollongong, NSW, Australia.
Suganthy VaradarajanBlacktown Cancer and Haematology Centre, Blacktown Hospital, Blacktown, NSW, Australia.
Senthilkumar GandhidasanIllawarra Cancer Care Centre, Wollongong, NSW, Australia.
Eric HauBlacktown Cancer and Haematology Centre, Blacktown Hospital, Blacktown, NSW, Australia.
Shalini Kavita VinodSouth Western Sydney Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia. shalini.vinod@health.nsw.gov.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are limited data on survival prediction models in contemporary inoperable non-small cell lung cancer (NSCLC) patients. The objective of this study was to develop and validate a survival prediction model in a cohort of inoperable stage I-III NSCLC patients treated with radiotherapy.

methodsData from inoperable stage I-III NSCLC patients diagnosed from 1/1/2016 to 31/12/2017 were collected from three radiation oncology clinics. Patient, tumour and treatment-related variables were selected for model inclusion using univariate and multivariate analysis. Cox proportional hazards regression was used to develop a 2-year overall survival prediction model, the South West Sydney Model (SWSM) in one clinic (n = 117) and validated in the other clinics (n = 144). Model performance, assessed internally and on one independent dataset, was expressed as Harrell's concordance index (c-index).

resultsThe SWSM contained five variables: Eastern Cooperative Oncology Group performance status, diffusing capacity of the lung for carbon monoxide, histological diagnosis, tumour lobe and equivalent dose in 2 Gy fractions. The SWSM yielded a c-index of 0.70 on internal validation and 0.72 on external validation. Survival probability could be stratified into three groups using a risk score derived from the model.

conclusionsA 2-year survival model with good discrimination was developed. The model included tumour lobe as a novel variable and has the potential to guide treatment decisions. Further validation is needed in a larger patient cohort.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAustraliaCohort StudiesHumansMultivariate AnalysisNeoplasm StagingNon-small cell lung cancerRadiotherapySurvival prediction

Identifiers

PMID35418206
PMCPMC9008968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.